The company said its revenue growth was supported by an 8% increase in underlying volumes.
8 Aug 2025|11:55 AM
Biosimilars revenue grew 18% YoY to ₹2,458 crore in the quarter. This growth was driven by sustained global demand
8 Aug 2025|11:34 AM
The company’s operating performance saw a notable improvement. EBITDA jumped 30.2% to ₹56 crore. This is compared to ₹43 crore in Q1FY25.
8 Aug 2025|11:13 AM
On the operational front, EBITDA rose 38.6% YoY to ₹525 crore. This is against ₹379 crore a year ago.
8 Aug 2025|10:51 AM
Revenue for the quarter rose modestly to ₹6,560 crore, a 3.6% increase over ₹6,334 crore reported a year earlier.
8 Aug 2025|10:36 AM
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
